MedTrace Logo

NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

NCT03462316 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-04-12

No results posted yet for this study

Summary

The main purpose of this trial is to investigate the safety and tolerability of NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）in the first-line treatment failed advanced bone and soft tissue sarcoma. The secondary purpose of this trial is to investigate the efficacy of NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）in the first-line treatment failed advanced bone and soft tissue sarcoma.

Conditions

  • Bone Sarcoma
  • Soft Tissue Sarcoma

Interventions

BIOLOGICAL

NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）

NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）

Sponsors & Collaborators

  • Guangdong Xiangxue Precision Medical Technology Co., Ltd.

    collaborator INDUSTRY

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-21
Primary Completion
2024-02-15
Completion
2024-05-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03462316 on ClinicalTrials.gov